These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4276573)

  • 41. Inhibition by apomorphine of prolactin secretion in patients with elevated serum prolactin.
    Martin JB; Lal S; Tolis G; Friesen HG
    J Clin Endocrinol Metab; 1974 Jul; 39(1):180-2. PubMed ID: 4835131
    [No Abstract]   [Full Text] [Related]  

  • 42. Ergot alkaloids as dopamine agonists: comparison in two rodent models.
    Anlezark G; Pycock C; Meldrum B
    Eur J Pharmacol; 1976 Jun; 37(2):295-302. PubMed ID: 986304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bromocriptine and dopamine-receptor stimulation.
    Dray A; Oakley NR
    J Pharm Pharmacol; 1976 Jul; 28(7):586-8. PubMed ID: 8616
    [No Abstract]   [Full Text] [Related]  

  • 44. New dopaminergic and potential anti-parkinson compounds, N,N-disubstituted beta-(3,4-dihydroxyphenyl)ethylamines.
    Ginos JZ; Cotzias GC; Doroski D
    J Med Chem; 1978 Feb; 21(2):160-5. PubMed ID: 563919
    [No Abstract]   [Full Text] [Related]  

  • 45. Rotatory behavior induced in nigra-lesioned rats by N-propylnoraporphine, apomorphine, and levodopa.
    Mendez JS; Cotzias GC; Finn BW; Dahl K
    Life Sci; 1975 Jun; 16(11):1737-42. PubMed ID: 1143000
    [No Abstract]   [Full Text] [Related]  

  • 46. N-Methyl-D-aspartate receptor participation in Parkinson's disease, a neurodegenerative disorder.
    Verma A; Kulkarni SK
    Ann N Y Acad Sci; 1995 Sep; 765():327. PubMed ID: 7486633
    [No Abstract]   [Full Text] [Related]  

  • 47. Enhancement of apomorphine-induced rotational behaviour in rats following the combination of 6-hydroxydopamine and electrolytic lesions in the substantia nigra.
    Watanabe H; Watanabe K
    Jpn J Pharmacol; 1979 Feb; 29(1):93-104. PubMed ID: 459160
    [No Abstract]   [Full Text] [Related]  

  • 48. Enkephalins and nigrostriatal function.
    Diamond BI; Borison RL
    Neurology; 1978 Nov; 28(11):1085-8. PubMed ID: 213743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopaminergic effects of lergotrile: possible involvement of a metabolite.
    McDevitt JT; Setler PE
    Neuropharmacology; 1980 Jun; 19(6):537-42. PubMed ID: 6105627
    [No Abstract]   [Full Text] [Related]  

  • 50. A preliminary report on the action of imipramine and antiparkinsonian agents on the open field behaviour of rats.
    Kulkarni SK; Dandiya PC
    Jpn J Pharmacol; 1974 Oct; 24(5):809-10. PubMed ID: 4477250
    [No Abstract]   [Full Text] [Related]  

  • 51. The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent.
    Koller WC; Weiner WJ; Diamond BI; Nausieda PA; Klawans HL
    Neuropharmacology; 1980 Sep; 19(9):831-7. PubMed ID: 7191490
    [No Abstract]   [Full Text] [Related]  

  • 52. A new central direct dopaminergic stimulant: 1-(Coumaran-5-yl methyl)-4-(2-thiazolyl) piperazine hydrochloride (S 3608).
    Poignant JC; Gressier H; Petitjean M; Regnier G; Canevari R
    Experientia; 1975 Oct; 31(10):1204-5. PubMed ID: 1243126
    [No Abstract]   [Full Text] [Related]  

  • 53. Studies on the central nervous system effects of agroclavine, an ergot alkaloid.
    Stone TW
    Arch Int Pharmacodyn Ther; 1973 Mar; 202(1):62-5. PubMed ID: 4694358
    [No Abstract]   [Full Text] [Related]  

  • 54. Proceedings: The role of dopamine in rotational behaviour produced by unilateral lesions of the locus coeruleus.
    Donaldson I; Dolphin A; Jenner P; Mardsen CK; Pycock C
    Br J Pharmacol; 1975 Oct; 55(2):290P. PubMed ID: 119
    [No Abstract]   [Full Text] [Related]  

  • 55. Bromocriptin and methylergometrine: pharmacological approach of the mechanism of their central effects.
    Puech AJ; Simon P; Chermat R; Boissier JR
    Pharmacol Res Commun; 1977 Mar; 9(3):299-306. PubMed ID: 577309
    [No Abstract]   [Full Text] [Related]  

  • 56. Participation of projections from substantia nigra reticulata to the lower brain stem in tuning behavior.
    Garcia-Munoz M; Patino P; Aguilar R; Arbuthnott G
    Exp Neurol; 1982 Nov; 78(2):380-90. PubMed ID: 6291976
    [No Abstract]   [Full Text] [Related]  

  • 57. Actions of levodopa and dopamine in the central nervous system.
    Sourkes TL
    JAMA; 1971 Dec; 218(13):1909-11. PubMed ID: 4398939
    [No Abstract]   [Full Text] [Related]  

  • 58. On the effects of apomorphine in mammals and frogs.
    Kuschinsky K
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):387-9. PubMed ID: 16912885
    [No Abstract]   [Full Text] [Related]  

  • 59. Effects of 2-BR-alpha-ergokryptine (CB 154) on sex-linked rejection of pituitary isografts in female C57BL mice.
    Hoshino K
    Experientia; 1973; 29(7):882-4. PubMed ID: 4146807
    [No Abstract]   [Full Text] [Related]  

  • 60. Correlation between brain dopamine levels and 1-dopa activity in anti-Parkinson tests.
    Horst WD; Pool WR; Spiegel HE
    Eur J Pharmacol; 1973 Mar; 21(3):337-42. PubMed ID: 4736076
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.